Biofrontera Net Income From Continuing Ops from 2010 to 2026
| BFRI Stock | USD 0.93 0.06 6.03% |
Net Loss | First Reported 2020-09-30 | Previous Quarter -5.3 M | Current Value -6.6 M | Quarterly Volatility 5.2 M |
Check Biofrontera financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biofrontera's main balance sheet or income statement drivers, such as Tax Provision of 30.4 K, Interest Income of 88.5 K or Depreciation And Amortization of 944.9 K, as well as many indicators such as Price To Sales Ratio of 0.18, Dividend Yield of 0.0 or PTB Ratio of 1.48. Biofrontera financial statements analysis is a perfect complement when working with Biofrontera Valuation or Volatility modules.
Biofrontera | Net Income From Continuing Ops | Build AI portfolio with Biofrontera Stock |
The Net Income From Continuing Ops trend for Biofrontera offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Biofrontera is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Biofrontera's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Biofrontera over the last few years. It is Biofrontera's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biofrontera's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Biofrontera Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (13,889,786) | |
| Coefficient Of Variation | (57.52) | |
| Mean Deviation | 5,321,227 | |
| Median | (10,982,000) | |
| Standard Deviation | 7,989,673 | |
| Sample Variance | 63.8T | |
| Range | 37.1M | |
| R-Value | (0.37) | |
| Mean Square Error | 58.8T | |
| R-Squared | 0.14 | |
| Significance | 0.14 | |
| Slope | (583,840) | |
| Total Sum of Squares | 1021.4T |
Biofrontera Net Income From Continuing Ops History
About Biofrontera Financial Statements
Investors use fundamental indicators, such as Biofrontera's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Biofrontera's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Net Loss | -16 M | -16.8 M |
Currently Active Assets on Macroaxis
When determining whether Biofrontera offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biofrontera's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biofrontera Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biofrontera Stock:Check out the analysis of Biofrontera Correlation against competitors. For more detail on how to invest in Biofrontera Stock please use our How to Invest in Biofrontera guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is there potential for Biotechnology market expansion? Will Biofrontera introduce new products? Factors like these will boost the valuation of Biofrontera. Projected growth potential of Biofrontera fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Biofrontera listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.50) | Revenue Per Share | Quarterly Revenue Growth (0.23) | Return On Assets | Return On Equity |
Understanding Biofrontera requires distinguishing between market price and book value, where the latter reflects Biofrontera's accounting equity. The concept of intrinsic value—what Biofrontera's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Biofrontera's price substantially above or below its fundamental value.
It's important to distinguish between Biofrontera's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biofrontera should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Biofrontera's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.